APA (7th ed.) Citation

MV, D., G, V., C, C., E, B., D, M., E, D. L., . . . V, G. (2026). PIK3CA mutations and first-line outcomes in endocrine-resistant HR+/HER2- metastatic breast cancer: A multicentric real-world study. European journal of cancer (Oxford, England : 1990), 234, 116194. https://doi.org/10.1016/j.ejca.2025.116194

Chicago Style (17th ed.) Citation

MV, Dieci, et al. "PIK3CA Mutations and First-line Outcomes in Endocrine-resistant HR+/HER2- Metastatic Breast Cancer: A Multicentric Real-world Study." European Journal of Cancer (Oxford, England : 1990) 234 (2026): 116194. https://doi.org/10.1016/j.ejca.2025.116194.

MLA (9th ed.) Citation

MV, Dieci, et al. "PIK3CA Mutations and First-line Outcomes in Endocrine-resistant HR+/HER2- Metastatic Breast Cancer: A Multicentric Real-world Study." European Journal of Cancer (Oxford, England : 1990), vol. 234, 2026, p. 116194, https://doi.org/10.1016/j.ejca.2025.116194.